Here are four things to know:
1. Baxter intends for Actifuse Flow to be used in the posterolateral spine, pelvis and extremities.
2. The bone graft substitute uses Baxter’s proprietary silicate-substituted technology, which is designed to enhance silicon levels to accelerate bone formation.
3. Actifuse Flow is the newest addition to Baxter’s osteobiologics surgery portfolio, which also includes Actifuse ABX, Actifuse Shape, Actifuse MIS and Altapore.
4. Baxter anticipates Actifuse Flow will be available to U.S. customers by year-end.
More articles on biologics:
Dr. Mark Mikhael studies stem cells for spine surgery – 4 insights
Spine biologics market to exceed $2.6B by 2022: 3 observations
SpinalCyte receives new patent for cartilage repair: 3 insights
At the Becker's 23rd Annual Spine, Orthopedic and Pain Management-Driven ASC + The Future of Spine Conference, taking place June 11-13 in Chicago, spine surgeons, orthopedic leaders and ASC executives will come together to explore minimally invasive techniques, ASC growth strategies and innovations shaping the future of outpatient spine care. Apply for complimentary registration now.
